Apr 17, 2017 12:01 pm UTC| Business
BASEL, Switzerland and CAMBRIDGE, Mass. and DURHAM, N.C., April 17, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,...
InvisibleShield Announces Curved Screen Protection for the Samsung Galaxy S8 and S8+
Apr 17, 2017 12:01 pm UTC| Business
SALT LAKE CITY, April 17, 2017 -- InvisibleShield®, the leading global brand and innovator in screen protection, today announced InvisibleShield Sapphire Defense® Curve and Glass Curvedesigned specifically to protect...
InvisibleShield Announces Curved Screen Protection for the Samsung Galaxy S8 and S8+
Apr 17, 2017 12:01 pm UTC| Business
SALT LAKE CITY, April 17, 2017 -- InvisibleShield®, the leading global brand and innovator in screen protection, today announced InvisibleShield Sapphire Defense® Curve and Glass Curvedesigned specifically to protect...
Barfresh Expands Customer Base with Bubba Gump Shrimp Co.
Apr 17, 2017 12:01 pm UTC| Business
BEVERLY HILLS, Calif., April 17, 2017 -- Barfresh Food Group, Inc. (OTCQB:BRFH), a manufacturer of frozen, ready-to-blend beverages, is announcing a new customer roll out with Landry’s, Inc. restaurant concept, Bubba...
Barfresh Expands Customer Base with Bubba Gump Shrimp Co.
Apr 17, 2017 12:01 pm UTC| Business
BEVERLY HILLS, Calif., April 17, 2017 -- Barfresh Food Group, Inc. (OTCQB:BRFH), a manufacturer of frozen, ready-to-blend beverages, is announcing a new customer roll out with Landry’s, Inc. restaurant concept, Bubba...
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Apr 17, 2017 12:01 pm UTC| Business
Company also Announces Discontinuation of Brontictuzumab Phase 1b Study OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results REDWOOD CITY, Calif., April 17, 2017 ...
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Apr 17, 2017 12:01 pm UTC| Business
Company also Announces Discontinuation of Brontictuzumab Phase 1b Study OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results REDWOOD CITY, Calif., April 17, 2017 ...